Brokers Offer Predictions for LAVA Therapeutics’ Q2 2022 Earnings (NASDAQ:LVTX)

LAVA Therapeutics (NASDAQ:LVTXGet Rating) – Stock analysts at Jefferies Financial Group boosted their Q2 2022 earnings estimates for shares of LAVA Therapeutics in a report released on Tuesday, May 17th. Jefferies Financial Group analyst C. Howerton now forecasts that the company will post earnings of ($0.78) per share for the quarter, up from their previous forecast of ($1.28). Jefferies Financial Group also issued estimates for LAVA Therapeutics’ Q3 2022 earnings at ($0.73) EPS, Q4 2022 earnings at ($0.78) EPS, FY2022 earnings at ($2.20) EPS, FY2023 earnings at ($2.56) EPS, FY2024 earnings at ($2.17) EPS, FY2025 earnings at ($1.95) EPS and FY2026 earnings at ($1.47) EPS.

Several other research firms have also issued reports on LVTX. SVB Leerink lifted their target price on LAVA Therapeutics to $25.00 and gave the company an “outperform” rating in a research note on Wednesday. Zacks Investment Research upgraded LAVA Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, April 23rd.

LVTX opened at $3.36 on Friday. The business’s 50-day moving average is $4.18 and its two-hundred day moving average is $5.19. LAVA Therapeutics has a 1 year low of $3.22 and a 1 year high of $12.92.

A hedge fund recently bought a new stake in LAVA Therapeutics stock. Point72 Asset Management L.P. bought a new position in shares of LAVA Therapeutics (NASDAQ:LVTXGet Rating) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 123,911 shares of the company’s stock, valued at approximately $734,000. Point72 Asset Management L.P. owned 0.49% of LAVA Therapeutics as of its most recent SEC filing. Institutional investors own 31.77% of the company’s stock.

About LAVA Therapeutics (Get Rating)

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.

Recommended Stories

Earnings History and Estimates for LAVA Therapeutics (NASDAQ:LVTX)

Receive News & Ratings for LAVA Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for LAVA Therapeutics and related companies with’s FREE daily email newsletter.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.